As Q4 Revenues Rise Sharply, Illumina Says Molecular Dx Will Make Initial Impact In 2008 | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
As Illumina gears up to launch its BeadXpress multiplexing platform within the next couple of months, company officials said last week that revenues from molecular diagnostics are not expected to make an impact on revenue until 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.